Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Over 1,800 killed since junta seized power in Burkina Faso, rights group says - 2Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- 36 Trail blazing Bicycles for Rough terrain Undertakings
- 4Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- 5Germany to create restitution council to return colonia-era acquired cultural artefacts
- Scientists find new clues to why female fertility declines with age
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
- This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- Best Pizza Beating: What's Your #1?
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Former biotech CEO sued over COVID vaccine alleged insider trading
- Reveal Less popular Authentic Realities You Didn't Learn in School
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
